Organon Bolsters Research & Development Expertise with Two Leadership Appointments
05 September 2023 - 4:00PM
Business Wire
Organon (NYSE: OGN), a global healthcare company with a focus on
women’s health, today announced the appointment of Juan Camilo
Arjona Ferreira, M.D., as Chief Medical Officer (CMO) and Charlotte
Owens, M.D., as Head of Medical Affairs and Outcomes Research,
strengthening the company’s global clinical and medical
capabilities, advancing external relationships and fueling efforts
to bring forward innovations to solve unmet health needs. Both
positions report directly to Sandra Milligan, M.D., J.D., Head of
Research and Development.
Dr. Arjona Ferreira brings over two decades of clinical research
and development experience and a strong background in women’s
health. Most recently, he was CMO of Myovant Sciences Inc., and has
previously held leadership roles in women’s health and other
therapeutic areas at Shionogi and Merck, known as MSD outside of
the United States and Canada. Earlier in his career, Dr. Arjona
Ferreira practiced as an OB-GYN in university hospitals and private
practice.
As the company’s CMO, Dr. Arjona Ferreira will be responsible
for leading Organon’s Global Clinical Development, Clinical Trial
Operations, Global Biostatistics, and Global Pharmacovigilance and
Safety Science teams. He will lead strategy and execution across
the company’s clinical development programs, support strong
clinical engagement with regulatory authorities, and build and
extend the company’s external stakeholder network around the
globe.
Dr. Arjona Ferreira commented, “I’m thrilled to be joining the
passionate Organon team at such a pivotal time as we’re building
and advancing an industry-leading pipeline with both early and
late-stage assets. I look forward to collaborating with our
incredible network of partners and colleagues worldwide to maximize
the potential of our innovations.”
Dr. Owens joins Organon with over a decade of experience in the
pharmaceutical and medical device industry, in addition to over 20
years practicing as an OB-GYN. Most recently, Dr. Owens served as
Vice President and Head of the Center for Health Equity &
Patient Affairs at Takeda. Prior to joining Takeda, Dr. Owens
served as a leader in clinical development and medical affairs at
AbbVie, Kimberly Clark, and Johnson & Johnson. In those roles,
she oversaw the direction, planning, execution, and interpretation
of clinical trials to deliver high-quality clinical data, with a
focus on women’s health, as well as the therapeutic area’s
scientific communications and educational efforts.
In this role, Dr. Owens will lead medical strategy as well as
support of marketed and pipeline products around the globe,
including health economics and outcomes research. She will develop
and foster relationships with external organizations and experts to
help ensure that Organon’s products continue to meet market needs,
yield desired outcomes, and enhance the organization’s reputation
with providers, payers and patients.
“Throughout my career, I have focused on addressing health
inequities and creating a more inclusive health ecosystem. It’s an
exciting and critical time to join this purpose-driven company that
is leading the way in bridging gaps in women’s health – an area
where attention, innovation and investment is so badly needed,” Dr.
Owens shared.
Added Dr. Milligan, “I’m confident Dr. Arjona Ferreira and Dr.
Owens will help us drive forward our mission of delivering
impactful medicines and solutions for a ‘healthier every day for
every woman’. With their deep expertise and strong relationships
across the global healthcare community, I’m thrilled to have them
both on board as we pursue our goal of accelerating innovation,
improving access and expanding choice to help address therapeutic
gaps around the world.”
About Organon
Organon is a global healthcare company formed to focus on
improving the health of women throughout their lives. Organon
offers more than 60 medicines and products in women’s health in
addition to a growing biosimilars business and a large franchise of
established medicines across a range of therapeutic areas.
Organon’s existing products produce strong cash flows that support
investments in innovation and future growth opportunities in
women’s health and biosimilars. In addition, Organon is pursuing
opportunities to collaborate with biopharmaceutical innovators
looking to commercialize their products by leveraging its scale and
presence in fast growing international markets.
Organon has a global footprint with significant scale and
geographic reach, world-class commercial capabilities, and
approximately 10,000 employees with headquarters located in Jersey
City, New Jersey.
For more information, visit http://www.organon.com and connect
with us on LinkedIn, Instagram, Twitter and Facebook.
Cautionary Note Regarding Forward-Looking Statements
Some statements and disclosures in this news release are
“forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements include all statements that do not
relate solely to historical or current facts and can be identified
by the use of words such as “goals”, "may," “expects,” “intends,”
“anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will,”
or words of similar meaning. These forward-looking statements
include statements regarding the expected benefits of the
employment of Dr. Arjona Ferreira and Dr. Owens, as well as
Organon’s expectations regarding its clinical and medical
capabilities, external stakeholder relationships, and business
development efforts. Such statements are based on Organon’s current
plans and expectations and are subject to a number of risks and
uncertainties that could cause its plans and expectations,
including actual results, to differ materially from the
forward-looking statements. Organon undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise. Additional factors
that could cause results to differ materially from those described
in the forward-looking statements can be found in Organon’s filings
with the Securities and Exchange Commission ("SEC"), including
Organon’s Annual Report on Form 10-K for the year ended December
31, 2022 and subsequent SEC filings, available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230905468265/en/
Media: Karissa Peer (614) 314-8094 Kate Vossen (732)
675-8448
Investor: Jennifer Halchak (201) 275-2711 Alex Arzeno (203)
550-3972
Organon (NYSE:OGN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Organon (NYSE:OGN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024